Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41 USD | +1.55% |
|
+2.64% | -31.22% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.22% | 4.9B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
+64.39% | 26.66B | |
-12.63% | 15.32B | |
-5.97% | 13.3B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
+2.40% | 9.06B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024